In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS, enjoy another 1 days of free consultation

 

Differences in clinical features of hypertrophic cardiomyopathy with or without left ventricular enlargement: a single-center and retrospective study

Session Rapid Fire 6 - Risk stratification and prognosis

Speaker Baiqing Ou

Congress : Heart Failure 2019

  • Topic : arrhythmias and device therapy
  • Sub-topic : Hypertrophic Cardiomyopathy
  • Session type : Rapid Fire Abstracts
  • FP Number : 1486

Authors : B Ou (Changsha,CN)

Authors:
B Ou1 , 1Hunan Provincial People's Hospital, Geriatric Medicine - Changsha - China ,

Citation:

Background: Few studies have focused on the clinical features of hypertrophic cardiomyopathy (HCM) with enlarged left ventricle (ELV). Hypothesis: HCM patients with ELV exhibit unique clinical features. Methods: Study participants were patients with HCM (n = 170), divided into two groups, ELV and normal sized left ventricle (NLV). Patients were also divided according to diagnosis of obstructive (n = 40), septal (n = 88), and apical (n =42) HCM. Age at diagnosis, sex, complications, electrocardiogram, symptoms, drug treatment, and echocardiographic parameters were compared among the NLV (n = 153) and ELV groups (n = 17). Results: The incidence of end-stage HCM (ES-HCM) among all HCM patients was 5.29%, and 10% in those with ELV. For all patients with HCM and those with septal HCM, there were more males with ELV than NLV. Of patients with HCM and septal HCM, left ventricular ejection fraction was significantly lower in the ELV group than the NLV group; accordingly, rates of diuretic use were higher in the ELV group than the NLV group. Among apical HCM patients, the left atrial diameter, incidence of atrial fibrillation or ST-T change, and rate of angiotensin converting enzyme inhibitor/angiotensin receptor blocker use in the ELV group were all higher than those in the NLV group. Conclusions: HCM patients with ELV are more likely to progress to ES-HCM than those with NLV. Additionally, ELV is more common in men than women and there are differences in the clinical features of different types of HCM with ELV.

Characteristics

ELV(n=17)

NLV(n=153)

p

AOVmax, cm/s

118.69±54.95

152.67±53.03

0.014

VE, cm/s 68.28±28.16 78.23±26.79 0.162
VA, cm/s 62.70±22.87 81.34±31.13 0.026

LVOTV, cm/s

161.25±95.38

245.76±153.44

0.174

LVOT PG, mmHg

13.21±13.48

35.46±36.81

0.032

EDV, ml

173.85±21.92

97.94±25.74

0.000

ESV, ml

69.13±24.17

31.23±11.85

0.000

LVEF, %

59.04±12.73

68.14±8.32

0.000

IVST, mm

17.32±10.54

16.25±5.84

0.517

LAd, mm

43.77±7.23

39.77±6.32

0.016

LVEDd, mm

59.20±3.20

45.67±5.52

0.000

LVESd, mm

37.03±10.82

28.33±4.39

0.004



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are